YY1 and neoplasm: Therefore, nitric oxide donors such as DETA-NONOate have great potential as antitumor therapy that targets YY1 and can enhance the cytotoxicity of antitumor therapies that depend on Fas-induced apoptotic tumor cell death, such as cell-mediated immunotherapy and immune checkpoint inhibition [165,166].